Brokerages expect that Steris PLC (NYSE:STE) will announce sales of $709.63 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Steris’ earnings. The lowest sales estimate is $707.00 million and the highest is $711.20 million. Steris reported sales of $681.19 million in the same quarter last year, which indicates a positive year over year growth rate of 4.2%. The business is expected to announce its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Steris will report full-year sales of $709.63 million for the current financial year, with estimates ranging from $2.61 billion to $2.62 billion. For the next financial year, analysts expect that the firm will report sales of $2.73 billion per share, with estimates ranging from $2.73 billion to $2.74 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Steris.
Steris (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.07 by $0.05. The company had revenue of $661.90 million for the quarter, compared to analysts’ expectations of $663.17 million. Steris had a net margin of 9.42% and a return on equity of 11.57%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 EPS.
STE has been the topic of several recent research reports. Northcoast Research set a $102.00 price objective on shares of Steris and gave the stock a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research raised shares of Steris from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. KeyCorp reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Steris in a research note on Thursday, February 8th. Finally, Raymond James Financial reaffirmed a “market perform” rating and issued a $100.00 price objective on shares of Steris in a research note on Wednesday, January 3rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Steris presently has a consensus rating of “Buy” and a consensus price target of $84.80.
Shares of Steris (NYSE STE) traded up $0.46 on Tuesday, hitting $95.54. 159,830 shares of the stock traded hands, compared to its average volume of 364,414. The firm has a market cap of $8,052.93, a PE ratio of 33.36 and a beta of 1.17. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.82 and a quick ratio of 2.22. Steris has a 12 month low of $67.55 and a 12 month high of $96.43.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be issued a $0.31 dividend. This represents a $1.24 annualized dividend and a dividend yield of 1.30%. This is a boost from Steris’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Tuesday, February 27th. Steris’s dividend payout ratio (DPR) is presently 43.51%.
In other Steris news, VP Sudhir K. Pahwa sold 2,000 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $92.09, for a total value of $184,180.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Karen L. Burton sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $85.59, for a total transaction of $128,385.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 78,415 shares of company stock valued at $7,178,536. Corporate insiders own 2.55% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its holdings in shares of Steris by 3.4% in the fourth quarter. BlackRock Inc. now owns 7,184,409 shares of the medical equipment provider’s stock worth $628,419,000 after buying an additional 239,200 shares during the period. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Steris by 0.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,487,376 shares of the medical equipment provider’s stock worth $130,101,000 after purchasing an additional 11,742 shares during the period. American Century Companies Inc. boosted its holdings in shares of Steris by 14.6% during the fourth quarter. American Century Companies Inc. now owns 1,194,167 shares of the medical equipment provider’s stock worth $104,454,000 after purchasing an additional 152,346 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Steris by 6.6% during the fourth quarter. Wells Fargo & Company MN now owns 1,105,452 shares of the medical equipment provider’s stock worth $96,694,000 after purchasing an additional 68,881 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Steris by 4.9% during the third quarter. Bank of New York Mellon Corp now owns 1,017,810 shares of the medical equipment provider’s stock worth $89,974,000 after purchasing an additional 47,682 shares during the period. Institutional investors own 89.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/analysts-anticipate-steris-plc-ste-will-announce-quarterly-sales-of-709-63-million.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Get a free copy of the Zacks research report on Steris (STE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.